Transforming growth factor-beta activity is potentiated by heparin via dissociation of the transforming growth factor-beta/alpha 2- macroglobulin inactive complex

doi:10.1083/jcb.109.1.441

This Article

	Full Text (PDF, 1222K)
	Alert me when this article is cited
	Citation Map

Services

	Email this article
	Similar articles in this journal
	Similar articles in PubMed
	Alert me to new content in the JCB
	Download to citation manager

Citing Articles

	Citing Articles via HighWire
	Citing Articles via CrossRef
	Citing Articles via Google Scholar

Google Scholar

	Articles by McCaffrey, T. A.
	Articles by Weksler, B. B.
	Search for Related Content

PubMed

	PubMed Citation
	Articles by McCaffrey, T. A.
	Articles by Weksler, B. B.


Social Bookmarking

	What's this?

ARTICLES

Transforming growth factor-beta activity is potentiated by heparin via dissociation of the transforming growth factor-beta/alpha 2- macroglobulin inactive complex

TA McCaffrey, DJ Falcone, CF Brayton, LA Agarwal, FG Welt and BB Weksler
Department of Medicine, Cornell University Medical College, New York 10021.

The control of smooth muscle cell (SMC) proliferation is determined by the combined actions of mitogens, such as platelet-derived growth factor, and the opposing action of growth inhibitory agents, such as heparin and transforming growth factor-beta (TGF-beta). The present studies identify an interaction between heparin and TGF-beta in which heparin potentiates the biological action of TGF-beta. Using a neutralizing antibody to TGF-beta, we observed that the short term antiproliferative effect of heparin depended upon the presence of biologically active TGF-beta. This effect was observed in rat and bovine aortic SMC and in CCL64 cells, but not in human saphenous vein SMC. Binding studies demonstrated that the addition of heparin (100 micrograms/ml) to medium containing 10% plasma-derived serum resulted in a 45% increase in the specific binding of 125I-TGF-beta to cells. Likewise, heparin induced a twofold increase in the growth inhibitory action of TGF-beta at concentrations of TGF-beta near its apparent dissociation constant. Using 125I-labeled TGF-beta, we demonstrated that TGF-beta complexes with the plasma component alpha 2- macroglobulin, but not with fibronectin. Heparin increases the electrophoretic mobility of TGF-beta apparently by freeing TGF-beta from its complex with alpha 2-macroglobulin. Dextran sulfate, another highly charged antiproliferative molecule, but not chondroitin sulfate or dermatan sulfate, similarly modified TGF-beta's mobility. Relatively high, antiproliferative concentrations of heparin (1-100 micrograms/ml) were required to dissociate the TGF-beta/alpha 2-macroglobulin complex. Thus, it appears that the antiproliferative effect of heparin may be partially attributed to its ability to potentiate the biological activity of TGF-beta by dissociating it from alpha 2-macroglobulin, which normally renders it inactive. We suggest that heparin-like agents may be important regulators of TGF-beta's biological activity.
Add to CiteULike CiteULike Add to Complore Complore Add to Connotea Connotea Add to Del.icio.us Del.icio.us Add to Digg Digg Facebook Add to Reddit Reddit Add to Technorati Technorati Twitter What's this?

This article has been cited by other articles:

Naumnik, B., Borawski, J., Pawlak, K., Mysliwiec, M. (2007). Enoxaparin but not unfractionated heparin causes a dose-dependent increase in plasma TGF-{beta}1 during haemodialysis: a cross-over study. Nephrol Dial Transplant 22: 1690-1696 [Abstract] [Full Text]
Sadick, N. S., Prieto, V. G., Shea, C. R., Nicholson, J., McCaffrey, T. (2001). Clinical and Pathophysiologic Correlates of 1064-nm Nd:YAG Laser Treatment of Reticular Veins and Venulectasias. Arch Dermatol 137: 613-617 [Abstract] [Full Text]
Smorenburg, S. M., Van Noorden, C. J. F. (2001). The Complex Effects of Heparins on Cancer Progression and Metastasis in Experimental Studies. Pharmacol. Rev. 53: 93-106 [Abstract] [Full Text]
GAMBARO, G., VAN DER WOUDE, F. J. (2000). Glycosaminoglycans: Use in Treatment of DiabeticNephropathy. J. Am. Soc. Nephrol. 11: 359-368 [Full Text]
Paka, L., Goldberg, I. J., Obunike, J. C., Choi, S. Y., Saxena, U., Goldberg, I. D., Pillarisetti, S. (1999). Perlecan Mediates the Antiproliferative Effect of Apolipoprotein E on Smooth Muscle Cells. AN UNDERLYING MECHANISM FOR THE MODULATION OF SMOOTH MUSCLE CELL GROWTH?. J. Biol. Chem. 274: 36403-36408 [Abstract] [Full Text]
Li, J., Foitzik, K., Calautti, E., Baden, H., Doetschman, T., Dotto, G. P. (1999). TGF-beta 3, but Not TGF-beta 1, Protects Keratinocytes against 12-O-Tetradecanoylphorbol-13-acetate-induced Cell Death in Vitro and in Vivo. J. Biol. Chem. 274: 4213-4219 [Abstract] [Full Text]
Wang, Y., Kovanen, P. T. (1999). Heparin Proteoglycans Released From Rat Serosal Mast Cells Inhibit Proliferation of Rat Aortic Smooth Muscle Cells in Culture. Circ. Res. 84: 74-83 [Abstract] [Full Text]
Choy, L., Derynck, R. (1998). The Type II Transforming Growth Factor (TGF)-beta Receptor-interacting Protein TRIP-1 Acts as a Modulator of the TGF-beta Response. J. Biol. Chem. 273: 31455-31462 [Abstract] [Full Text]
Griswold-Prenner, I., Kamibayashi, C., Maruoka, E. M., Mumby, M. C., Derynck, R. (1998). Physical and Functional Interactions between Type I Transforming Growth Factor beta �Receptors and Balpha , a WD-40 Repeat Subunit of Phosphatase 2A. Mol. Cell. Biol. 18: 6595-6604 [Abstract] [Full Text]
Sindermann, J. R., March, K. L. (1998). Heparin Responsiveness In Vitro as a Prognostic Tool for Vascular Graft Stenosis : A Tale of Two Cell Types?. Circulation 97: 2486-2490 [Full Text]
Grainger, D., Metcalfe, J., Grace, A., Mosedale, D. (1998). Transforming growth factor-beta dynamically regulates vascular smooth muscle differentiation in vivo. J. Cell Sci. 111: 2977-2988 [Abstract]
Ueba, H., Kawakami, M., Yaginuma, T. (1997). Shear Stress as an Inhibitor of Vascular Smooth Muscle Cell Proliferation : Role of Transforming Growth Factor-�1 and Tissue-Type Plasminogen Activator. Arterioscler. Thromb. Vasc. Bio. 17: 1512-1516 [Abstract] [Full Text]
Lyon, M., Rushton, G., Gallagher, J. T. (1997). The Interaction of the Transforming Growth Factor-beta s with Heparin/Heparan Sulfate Is Isoform-specific. J. Biol. Chem. 272: 18000-18006 [Abstract] [Full Text]
Nakata, A., Miyagawa, J.-i., Yamashita, S., Nishida, M., Tamura, R., Yamamori, K., Nakamura, T., Nozaki, S., Kameda-Takemura, K., Kawata, S., Taniguchi, N., Higashiyama, S., Matsuzawa, Y. (1996). Localization of Heparin-Binding Epidermal Growth Factor�Like Growth Factor in Human Coronary Arteries: Possible Roles of HB-EGF in the Formation of Coronary Atherosclerosis. Circulation 94: 2778-2786 [Abstract] [Full Text]
Geary, R. L., Koyama, N., Wang, T. W., Vergel, S., Clowes, A. W. (1995). Failure of Heparin to Inhibit Intimal Hyperplasia in Injured Baboon Arteries : The Role of Heparin-Sensitive and -Insensitive Pathways in the Stimulation of Smooth Muscle Cell Migration and Proliferation. Circulation 91: 2972-2981 [Abstract] [Full Text]
Hoffman, R, Paper, D., Donaldson, J, Alban, S, Franz, G (1995). Characterisation of a laminarin sulphate which inhibits basic fibroblast growth factor binding and endothelial cell proliferation. J. Cell Sci. 108: 3591-3598 [Abstract]
Kaner, R., Baird, A, Mansukhani, A, Basilico, C, Summers, B., Florkiewicz, R., Hajjar, D. (1990). Fibroblast growth factor receptor is a portal of cellular entry for herpes simplex virus type 1. Science 248: 1410-1413 [Abstract]